Neuropace Net Worth
Neuropace Net Worth Breakdown | NPCE |
Neuropace Net Worth Analysis
Neuropace's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Neuropace's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Neuropace's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Neuropace's net worth analysis. One common approach is to calculate Neuropace's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Neuropace's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Neuropace's net worth. This approach calculates the present value of Neuropace's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Neuropace's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Neuropace's net worth. This involves comparing Neuropace's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Neuropace's net worth relative to its peers.
Enterprise Value |
|
To determine if Neuropace is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Neuropace's net worth research are outlined below:
| Neuropace appears to be risky and price may revert if volatility continues | |
| Neuropace has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 65.42 M. Net Loss for the year was (32.96 M) with profit before overhead, payroll, taxes, and interest of 56.44 M. | |
| Neuropace currently holds about 92.41 M in cash with (19.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.72. | |
| Roughly 65.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: NeuroPace Completes Repurchase of 5.3 Million Shares of Its Common Stock from KCK Ltd. |
Neuropace uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Neuropace. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Neuropace's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Neuropace Target Price Consensus
Neuropace target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Neuropace's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 6 | Strong Buy |
Most Neuropace analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Neuropace stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Neuropace, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationNeuropace Target Price Projection
Neuropace's current and average target prices are 13.84 and 16.17, respectively. The current price of Neuropace is the price at which Neuropace is currently trading. On the other hand, Neuropace's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Neuropace Market Quote on 25th of February 2025
Target Price
Analyst Consensus On Neuropace Target Price
Know Neuropace's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Neuropace is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Neuropace backward and forwards among themselves. Neuropace's institutional investor refers to the entity that pools money to purchase Neuropace's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Fmr Inc | 2024-12-31 | 249.7 K | Northern Trust Corp | 2024-12-31 | 184.8 K | State Street Corp | 2024-12-31 | 148.3 K | Jane Street Group Llc | 2024-12-31 | 100.1 K | Renaissance Technologies Corp | 2024-12-31 | 86.3 K | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 57.1 K | Gsa Capital Partners Llp | 2024-12-31 | 56.4 K | Goldman Sachs Group Inc | 2024-12-31 | 42.3 K | Charles Schwab Investment Management Inc | 2024-12-31 | 36.5 K | Kck Ltd | 2024-12-31 | 5.3 M | Orbimed Advisors, Llc | 2024-09-30 | 3.4 M |
Follow Neuropace's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 420.17 M.Market Cap |
|
Project Neuropace's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.28) | (0.29) | |
| Return On Capital Employed | (0.34) | (0.32) | |
| Return On Assets | (0.28) | (0.29) | |
| Return On Equity | (1.83) | (1.74) |
When accessing Neuropace's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Neuropace's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Neuropace's profitability and make more informed investment decisions.
Please note, the presentation of Neuropace's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Neuropace's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Neuropace's management manipulating its earnings.
Evaluate Neuropace's management efficiency
Neuropace has return on total asset (ROA) of (0.1474) % which means that it has lost $0.1474 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.1455) %, meaning that it created substantial loss on money invested by shareholders. Neuropace's management efficiency ratios could be used to measure how well Neuropace manages its routine affairs as well as how well it operates its assets and liabilities. As of February 25, 2025, Return On Tangible Assets is expected to decline to -0.29. The current year's Return On Capital Employed is expected to grow to -0.32. At present, Neuropace's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 1.23, whereas Non Currrent Assets Other are forecasted to decline to about 317.9 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.72 | 0.75 | |
| Tangible Book Value Per Share | 0.72 | 0.75 | |
| Enterprise Value Over EBITDA | (12.65) | (13.28) | |
| Price Book Value Ratio | 11.61 | 12.19 | |
| Enterprise Value Multiple | (12.65) | (13.28) | |
| Price Fair Value | 11.61 | 12.19 | |
| Enterprise Value | 369 M | 433.9 M |
Neuropace showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Enterprise Value Revenue 5.8073 | Revenue | Quarterly Revenue Growth 0.282 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Neuropace insiders, such as employees or executives, is commonly permitted as long as it does not rely on Neuropace's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Neuropace insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Neuropace Corporate Filings
F4 | 20th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 18th of February 2025 Other Reports | ViewVerify | |
| 11th of February 2025 Other Reports | ViewVerify | |
8K | 28th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Neuropace Earnings Estimation Breakdown
The calculation of Neuropace's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Neuropace is estimated to be -0.24565 with the future projection ranging from a low of -0.2575 to a high of -0.235. Please be aware that this consensus of annual earnings estimates for Neuropace is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.26 Lowest | Expected EPS | -0.23 Highest |
Neuropace Earnings Projection Consensus
Suppose the current estimates of Neuropace's value are higher than the current market price of the Neuropace stock. In this case, investors may conclude that Neuropace is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Neuropace's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 7 | 80.02% | -0.19 | -0.24565 | -0.98 |
Neuropace Earnings History
Earnings estimate consensus by Neuropace analysts from Wall Street is used by the market to judge Neuropace's stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Neuropace's upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.Neuropace Quarterly Gross Profit |
|
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Neuropace's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Neuropace Earnings per Share Projection vs Actual
Actual Earning per Share of Neuropace refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Neuropace predict the company's earnings will be in the future. The higher the earnings per share of Neuropace, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Neuropace Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Neuropace, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Neuropace should always be considered in relation to other companies to make a more educated investment decision.Neuropace Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Neuropace's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-12 | 2024-09-30 | -0.27 | -0.19 | 0.08 | 29 | ||
2024-08-13 | 2024-06-30 | -0.3 | -0.26 | 0.04 | 13 | ||
2024-05-08 | 2024-03-31 | -0.32 | -0.32 | 0.0 | 0 | ||
2024-03-05 | 2023-12-31 | -0.31 | -0.23 | 0.08 | 25 | ||
2023-11-06 | 2023-09-30 | -0.41 | -0.28 | 0.13 | 31 | ||
2023-08-08 | 2023-06-30 | -0.46 | -0.36 | 0.1 | 21 | ||
2023-05-04 | 2023-03-31 | -0.46 | -0.41 | 0.05 | 10 | ||
2023-03-02 | 2022-12-31 | -0.49 | -0.45 | 0.04 | 8 | ||
2022-11-08 | 2022-09-30 | -0.53 | -0.48 | 0.05 | 9 | ||
2022-08-11 | 2022-06-30 | -0.44 | -0.52 | -0.08 | 18 | ||
2022-05-12 | 2022-03-31 | -0.44 | -0.47 | -0.03 | 6 | ||
2022-03-10 | 2021-12-31 | -0.33 | -0.44 | -0.11 | 33 | ||
2021-11-10 | 2021-09-30 | -0.3 | -0.34 | -0.04 | 13 | ||
2021-08-12 | 2021-06-30 | -0.34 | -0.48 | -0.14 | 41 | ||
2021-06-03 | 2021-03-31 | -0.28 | -32.73 | -32.45 | 11589 | ||
2021-03-24 | 2020-12-31 | 0 | -0.17 | -0.17 | 0 |
Neuropace Corporate Management
| Irina Ridley | Chief Secretary | Profile | |
| Chi Nguyen | VP Marketing | Profile | |
| Kelley Nicholas | Vice Sales | Profile | |
| Michael Favet | CEO Pres | Profile | |
| Katie Keller | Vice Marketing | Profile | |
| Rebecca Kuhn | VP CFO | Profile | |
| Martha MD | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuropace. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuropace. If investors know Neuropace will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuropace listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.98) | Revenue Per Share | Quarterly Revenue Growth 0.282 | Return On Assets | Return On Equity |
The market value of Neuropace is measured differently than its book value, which is the value of Neuropace that is recorded on the company's balance sheet. Investors also form their own opinion of Neuropace's value that differs from its market value or its book value, called intrinsic value, which is Neuropace's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuropace's market value can be influenced by many factors that don't directly affect Neuropace's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuropace's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuropace is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuropace's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.